Modelling Rock Fracture Induced By Hydraulic Pulses

Soft cyclic hydraulic fracturing has become an effective technology used in subsurface energy extraction which utilises cyclic hydraulic flow pressure to fracture rock. This new technique induces fatigue of rock to reduce the breakdown pressure and potentially the associated risk of seismicity. To control the fracturing process and achieve desirable fracture networks for enhanced permeability, the rock response under cyclic hydraulic stimulation needs to be understood. However, the mechanism for cyclic stimulation-induced fatigue of rock is rather unclear and to date there is no implementation of fatigue degradation in modelling the rock response under hydraulic cyclic loading. This makes accurate prediction of rock fracture under cyclic hydraulic pressure impossible. This paper develops a numerical method to model rock fracture induced by hydraulic pulses with consideration of rock fatigue. The fatigue degradation is based on S–N curves (S for cyclic stress and N for cycles to failure) and implemented into the constitutive relationship for fracture of rock using in-house FORTRAN scripts and ABAQUS solver. The cohesive crack model is used to simulate discrete crack propagation in the rock which is coupled with hydraulic flow and pore pressure capability. The developed numerical model is validated via experimental results of pulsating hydraulic fracturing of the rock. The effects of flow rate and frequency of cyclic injection on borehole pressure development are investigated. A new loading strategy for pulsating hydraulic fracturing is proposed. It has been found that hydraulic pulses can reduce the breakdown pressure of rock by 10–18% upon 10–4000 cycles. Using the new loading strategy, a slow and steady rock fracture process is obtained while the failure pressure is reduced

Rate-dependence of the compressive and tensile strength of granites

The strength and rupture of geomaterials are integral to subsurface engineering practices, such as those required to optimise geothermal energy extraction. Of particular importance is the time- and strain-rate-dependence of material strength, which dictates the energy released upon failure, and impacts the magnitude of induced seismicity, fracture architecture and thus hydraulic conductivity and system permeability. Here, we performed a series of uniaxial compression and Brazilian tensile strength measurements at a range of deformation rates in order to constrain the impact of strain rate on the strength of G603 granite. The dense, low permeability, medium-grained granites were mechanically tested at 4 strain rates (or diametric equivalent strain rates in the case of Brazilian tests) from 10−5 to 10−2 s−1, such that sample failure was achieved in anything from below 1s at the fastest rate in tension, to over 1000s at the slowest rate in compression. The applied rates encompassed those recommended by ISRM and ASTM material testing standards for compressive and Brazilian tensile testing. We found a significant rate strengthening effect, whereby compressive and tensile strength both increased by approximately 35 % across the 4 orders of magnitude of strain rate tested. We found that the static Young's modulus remained relatively constant across this range of deformation rates, however variability was reduced at faster rates, owing to the reduced time for equilibration of the system to imposed stresses. The lower strength at slower strain rates causes smaller stress drops, indicating that rocks driven to compressive and tensile failure at slower rates release less energy upon failure. Such constraints of the strain-rate-dependence of material strength, in contrast to the use of standardised material characteristics conventionally used in Engineering Geology applications, will prove useful as we develop increasingly sophisticated strategies such as cyclic soft stimulation to access resources using less energy, whilst reducing environmental risk and producing less waste.</p

Estimating geological CO2 storage security to deliver on climate mitigation

Carbon capture and storage (CCS) can help nations meet their Paris CO2 reduction commitments cost-effectively. However, lack of confidence in geologic CO2 storage security remains a barrier to CCS implementation. Here we present a numerical program that calculates CO2 storage security and leakage to the atmosphere over 10,000 years. This combines quantitative estimates of geological subsurface CO2 retention, and of surface CO2 leakage. We calculate that realistically well-regulated storage in regions with moderate well densities has a 50% probability that leakage remains below 0.0008% per year, with over 98% of the injected CO2 retained in the subsurface over 10,000 years. An unrealistic scenario, where CO2 storage is inadequately regulated, estimates that more than 78% will be retained over 10,000 years. Our modelling results suggest that geological storage of CO2 can be a secure climate change mitigation option, but we note that long-term behaviour of CO2 in the subsurface remains a key uncertainty

Trial of Dexamethasone for Chronic Subdural Hematoma

BACKGROUND: Chronic subdural hematoma is a common neurologic disorder that is especially prevalent among older people. The effect of dexamethasone on outcomes in patients with chronic subdural hematoma has not been well studied. METHODS: We conducted a multicenter, randomized trial in the United Kingdom that enrolled adult patients with symptomatic chronic subdural hematoma. The patients were assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the hematoma was made by the treating clinician. The primary outcome was a score of 0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; scores range from 0 (no symptoms) to 6 (death). RESULTS: From August 2015 through November 2019, a total of 748 patients were included in the trial after randomization - 375 were assigned to the dexamethasone group and 373 to the placebo group. The mean age of the patients was 74 years, and 94% underwent surgery to evacuate their hematomas during the index admission; 60% in both groups had a score of 1 to 3 on the modified Rankin scale at admission. In a modified intention-to-treat analysis that excluded the patients who withdrew consent for participation in the trial or who were lost to follow-up, leaving a total of 680 patients, a favorable outcome was reported in 286 of 341 patients (83.9%) in the dexamethasone group and in 306 of 339 patients (90.3%) in the placebo group (difference, -6.4 percentage points [95% confidence interval, -11.4 to -1.4] in favor of the placebo group; P = 0.01). Among the patients with available data, repeat surgery for recurrence of the hematoma was performed in 6 of 349 patients (1.7%) in the dexamethasone group and in 25 of 350 patients (7.1%) in the placebo group. More adverse events occurred in the dexamethasone group than in the placebo group. CONCLUSIONS: Among adults with symptomatic chronic subdural hematoma, most of whom had undergone surgery to remove their hematomas during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and more adverse events than placebo at 6 months, but fewer repeat operations were performed in the dexamethasone group. (Funded by the National Institute for Health Research Health Technology Assessment Programme; Dex-CSDH ISRCTN number, ISRCTN80782810.)

Trial of Dexamethasone for Chronic Subdural Hematoma

BACKGROUND: Chronic subdural hematoma is a common neurologic disorder that is especially prevalent among older people. The effect of dexamethasone on outcomes in patients with chronic subdural hematoma has not been well studied. METHODS: We conducted a multicenter, randomized trial in the United Kingdom that enrolled adult patients with symptomatic chronic subdural hematoma. The patients were assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the hematoma was made by the treating clinician. The primary outcome was a score of 0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; scores range from 0 (no symptoms) to 6 (death). RESULTS: From August 2015 through November 2019, a total of 748 patients were included in the trial after randomization - 375 were assigned to the dexamethasone group and 373 to the placebo group. The mean age of the patients was 74 years, and 94% underwent surgery to evacuate their hematomas during the index admission; 60% in both groups had a score of 1 to 3 on the modified Rankin scale at admission. In a modified intention-to-treat analysis that excluded the patients who withdrew consent for participation in the trial or who were lost to follow-up, leaving a total of 680 patients, a favorable outcome was reported in 286 of 341 patients (83.9%) in the dexamethasone group and in 306 of 339 patients (90.3%) in the placebo group (difference, -6.4 percentage points [95% confidence interval, -11.4 to -1.4] in favor of the placebo group; P = 0.01). Among the patients with available data, repeat surgery for recurrence of the hematoma was performed in 6 of 349 patients (1.7%) in the dexamethasone group and in 25 of 350 patients (7.1%) in the placebo group. More adverse events occurred in the dexamethasone group than in the placebo group. CONCLUSIONS: Among adults with symptomatic chronic subdural hematoma, most of whom had undergone surgery to remove their hematomas during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and more adverse events than placebo at 6 months, but fewer repeat operations were performed in the dexamethasone group. (Funded by the National Institute for Health Research Health Technology Assessment Programme; Dex-CSDH ISRCTN number, ISRCTN80782810.)

A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)

Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 13/15/02) and is published in full in Health Technology Assessment; Vol. 28, No. 12. See the NIHR Funding and Awards website for further award information.Peer reviewe

Trial of Dexamethasone for Chronic Subdural Hematoma

(Trial funded by NIHR, Dex-CSDH Current Controlled Trials number ISRCTN80782810). ACKNOWLEDGEMENTS In memory of Mrs. Kate Massey, who was the patient representative involved in study design. Peter Hutchinson is supported by a Research Professorship and Senior Investigator Award from the NIHR, the NIHR Cambridge Biomedical Research Centre, and the Royal College of Surgeons of England. Ellie Edlmann is supported by the Royal College of Surgeons of England. Angelos Kolias is supported by a Lectureship, School of Clinical Medicine, University of Cambridge and the Royal College of Surgeons of England. SUPPORT This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Peer reviewedPublisher PD